Skip to main content
. 2021 Nov 19;9(1):2103836. doi: 10.1002/advs.202103836

Figure 5.

Figure 5

a) Schematic illustration showing the synergistic immunotherapy using the ROS‐sensitive complexes for controlled sequential release of aCD47 and aPD1 in the TME. b–e) Flow cytometry analyzed the percentage of CD45+ cells (b), M2‐like macrophages (CD206hiF4/80+CD11b+) (c), CD4+Foxp3+ T cells (d), and CD8+ T cells (e) in B16‐F10 tumors. Reproduced with permission.[ 65 ] Copyright 2019, American Chemical Society. f) Schematic illustration the mechanism of P3C‐Asp in combination with aPD‐1 in cancer immunotherapy. g)The proposed release mechanism of P3C‐Asp in the presence of H2O2. h) In vitro aspirin release profiles of P3C‐Asp in phosphate buffer with Tween 80 (0.2%, w/v) at four conditions: pH 7.4, pH 6.8 with 100 × 10−6 m H2O2, and pH 6.8 with 10 × 10−3 m H2O2, n = 3. Reproduced with permission.[ 68 ] Copyright 2019, Chinese Chemical Society. p‐Values: *p < 0.05; **p < 0.01; ***p < 0.001.